Sandip Vasavada, MD
Dr. Vasavada is Co-Section Head, Section of Voiding Dysfunction and Female Urology, Glickman Urological Institute, The Cleveland Clinic Foundation, Cleveland, OH. |
 | Sacral neuromodulation: State-of-the-art strategies and troubleshooting techniques
February 1, 2006
By: Adonis Hijaz, MD
,
Sandip Vasavada, MD
,
Raymond Rackley, MD
Is bilateral stimulation more effective than unilateral lead placement? What should be done for patients who report pain at the lead site? How can I reduce the risk of stage 1 complications? The authors offer state-of-the-art advice on these and other issues affecting patients undergoing this minimally invasive treatment for lower urinary tract dysfunctions. |
Current and future pharmacotherapy for the overactive bladder
June 1, 2005
By: Adonis Hijaz, MD
,
Sandip Vasavada, MD
,
Raymond R. Rackley, MD
An estimated 1 out of 6 adults has an overactive bladder that may have a clinically significant impact on his or her health and quality of life. First-line pharmacologic treatment of primary OAB has traditionally involved the use of anticholinergic drugs with various muscarinic receptor affinities. Future OAB therapies may offer the ability to produce "target organ"-specific agents that address individual or combination mechanisms that contribute to the micturition process. |
| 
E-mail Alerts
RSS Feeds
Practice Tools
